Evidence map›Paper›PMID 38063923›Full record

ArticleDiscover oncology2023

Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma.

Yusuke Uchinami, Koichi Yasuda, Satoshi Kano, Manami Otsuka, Seijiro Hamada, Takayoshi Suzuki, Nayuta Tsushima, Shuhei Takahashi, Yoshihiro Fujita, Tomohiko Miyazaki and 6 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Yusuke UchinamiDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Koichi YasudaDepartment of Radiation Oncology, Hokkaido University Hospital, North 14 West 5, Kita-Ku, Sapporo, Hokkaido, 060-8648, Japan. yasuda07@gmail.com.
Satoshi KanoDepartment of Otolaryngology-Head and Neck Surgery, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Manami OtsukaDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Seijiro HamadaDepartment of Otolaryngology-Head and Neck Surgery, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Takayoshi SuzukiDepartment of Otolaryngology-Head and Neck Surgery, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Nayuta TsushimaDepartment of Otolaryngology-Head and Neck Surgery, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Shuhei TakahashiDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Yoshihiro FujitaDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Tomohiko MiyazakiDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Hajime HigakiDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Jun TaguchiDepartment of Medical Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Yasushi ShimizuDepartment of Medical Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Tomohiro SakashitaDepartment of Otolaryngology-Head and Neck Surgery, Kushiro City General Hospital, Syunkodai 1-12, Kushiro, Hokkaido, 085-0822, Japan.
Akihiro HommaDepartment of Otolaryngology-Head and Neck Surgery, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Hidefumi AoyamaDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Hokkaido University · JPHokkaido University Hospital · JPKushiro City General Hospital · JP

Funding

Japan Society for the Promotion of Science 19K08088Japan Society for the Promotion of Science 23K14857
6 · The paper itself

Abstract

backgroundTri-weekly cisplatin and radiotherapy (CDDP + RT) is a standard of care for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) but is sometimes challenging to complete in older patients. Weekly CDDP + RT has shown mild toxicity compared to tri-weekly CDDP + RT for LA-HNSCC and is a promising option for older adults. We aimed to report the treatment outcomes and prognostic factors in patients with LA-HNSCC treated with weekly CDDP + RT.

methodsWe analyzed patients aged ≥ 70 years who started weekly CDDP + RT for LA-HNSCC between July 2006 and October 2022. LA-HNSCC includes cancer in the oropharynx, hypopharynx, or larynx with a clinical stage of 3 or 4 without distant metastases based on the Union for International Cancer Control staging system 8th edition. The radiation dose of 70 Gy was delivered in 35 fractions by 3-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy. The primary endpoint was the 3-year overall survival (OS), and the secondary endpoints were the 3-year progression-free survival (PFS) and 3-year cause-specific survival (CSS). The Kaplan-Meier method was used to calculate survival rates, and the log-rank test was used to evaluate statistical significance. A Cox proportional hazards model was used for the multivariate analysis of prognostic factors.

resultsThe median age of the 49 patients was 72 (range: 70-78) years. The median CDDP dose was 200 (40-280) mg/ m

conclusionsWeekly CDDP + RT in older patients led to good survival outcomes with an acceptable rate of adverse events. CDDP should be administered at a dose of at least 200 mg/m

Indexed as

ChemoradiotherapyHead and neck cancerOlder patientsTreatment outcomesWeekly cisplatin

Identifiers

PMID38063923
PMCPMC10709267
OpenAlexW4389481933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.